This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Jose Beceiro, MD; Joseph R. Bianchine, MD; Jack Dunn, Jr., MD; Abraham Flemenbaum, MD; William H. Gordon, Jr., MD; Samuel King, MD; Carlos Lamar, MD; Frank M. Ryburn, Jr., MD; Laddawan Sunyapridakul, MD

JAMA. 1975;233(11):1198-1201.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

Dr. Lamar: Our discussion today will focus on the need to individualize the total management of a parkinsonian patient to assure an optimal therapeutic benefit. This approach is especially important because of the well-recognized, remarkable variation in therapeutic response that exists among parkinsonian patients and even within the same patient from day to day.

Perhaps 15% of parkinsonian patients do not achieve even a modicum of desired therapeutic response from one or more of the antiparkinsonian drugs they receive, while an equal proportion of patients derive intolerable drug side-effects—sometimes at low doses. Other patients may suffer from drug-drug interactions following coadministration of two or more antiparkinsonian drugs. The objective of this round is to discuss factors that must be considered to achieve optimal therapeutic results in the management of parkinsonism.

The moderator of this conference will be Dr. Joseph R. Bianchine.

Dr. Bianchine: Dr. Gordon, will you define Parkinson disease . . . [Full Text PDF of this Article]

Footnotes
Reprint requests to Department of Pharmacology, Ohio State University School of Medicine, Columbus, OH 43210 (Dr. Bianchine).

Edited by John D. Archer, MD, Senior Editor.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?